What Predicts Disability Progression in Multiple Sclerosis?

Slides:



Advertisements
Similar presentations
Corpus Callosum Damage Predicts Disability Progression and Cognitive Dysfunction in Primary-Progressive MS After Five Years.
Advertisements

Study Design 121 Relapsing-remitting MS patients randomized to –Stress Management Therapy MS active treatment* 16 individual sessions conducted over 24.
MULTIPLE SCLEROSIS CLAIRE BISCHOFF, ASHLEY FOLDEN, AND CASSIE NEWMAN.
Dementia Research Group MRI, rates of atrophy and Alzheimer’s disease Nick Fox Dementia Research Group Institute of Neurology, UCL Queen Square, London.
1 Patient Treatment Numbers for Beike Biotech Chinese Nationals and Foreigners.
CHAPTER 23: Neurological Disorders in Women. Introduction Gender differences exist in the development and expression of several neurological disorders,
MRI as a Potential Surrogate Marker in the ADCS MCI Trial
Dennis Bourdette, MD VA MS Center of Excellence-West and
Multiple Sclerosis By: Sandra Bachaalany MIM Virtual Camp Project.
Multiple Sclerosis (MS) a serious, chronic and debilitating disease What is MS? A disease of the brain and spinal cord.
NEDA epoch analysis of patients with relapsing multiple sclerosis treated with ocrelizumab: Results from the OPERA I and OPERA II, phase III studies G.
CNS Disorders and The Dementias
Applying the New Multiple Sclerosis Guidelines to Clinical Practice
Multiple sclerosis: Oral Therapies and Beyond
Claire Bischoff, Ashley folden, and Cassie Newman
Neuro-ophthalmology.
Glaucoma.
Silent No More:.
Exploring Early Combination Therapy in PAH
Highlights From the 2017 Annual European MS Meeting
Perspectives on Key MS Data From the Annual European MS Meeting
MS Highlights From the 2017 Annual Neurology Meeting
Program Goals Teriflunomide: Pooled Safety Data.
Challenges in the Diagnosis of MS: Physician and Nurse Perspectives
Glaucoma Progression.
Changing the IBD Paradigm
Modifying Disease Course in Alzheimer's Disease
Current Controversies in Multiple Sclerosis Management
New Challenges Facing Multiple Sclerosis Nurses
What’s the Big Deal About Brain Atrophy and Neurodegeneration in RRMS?
T-Cell Directed Therapy in MS
Clinical Cases in Glaucoma Treatment
Challenges in Managing Progressive Multiple Sclerosis
Assessing Disease Progression in MS Treatment
Precision Management of RA and Comorbidities
Novel Therapies for the Treatment of MS
Management Challenges in CLL
The future of urate-lowering strategies for gout
Is RA Treatment Addressing the Real Needs of Patients?
Should I Stay or Should I Go?
Discussion and Concluding Remarks
Demographics of IPF in the USa-d
Treating to Target in MS
EARLY Combination Therapy in PAH: What Every Cardiologist Needs to Know.
Systemic Sclerosis With Interstitial Lung Disease
Expert Perspectives on the Clinical Use of Immune Reconstitution vs Escalation Therapy for MS.
Figure 1 Evolution of multiple sclerosis
Program Goals Overview Is NEDA a Reasonable Target?
Nat. Rev. Neurol. doi: /nrneurol
Intro: Biomarkers in RA
Optimizing Outcomes in Crohn Disease
New ELN Recommendations
NEDA 2-Year Endpoint: Not a Predictor of Long-Term Stability?
Are We Making Progress in the Management of Huntington Disease?
Inhaled Antibiotics for Patients With CF in the Era of CFTR Modulators
Improving Outcomes in Patients With SSc-ILD
Secondary Progressive Multiple Sclerosis: What Do We Know and Where Are We Heading?
Program Goals Overview Is NEDA a Reasonable Target?
Novel Therapeutics in MS
Clinical Challenges in the Patient With Relapsed Multiple Myeloma
PICO model for developing EBM questions
A Closer Look.
Clinical Pearls in the Management of Patients With Advanced Non-Small Cell Lung Cancer.
MS, Age, and Immune Function
Using Biomarkers in MS: Initiating With the Right Therapy in Clinical Practice.
NAFLD and NASH in Europe and Canada
Understanding the Role of Disability in MS Management
The Changing Face of Multiple Sclerosis: What Are the Experts Looking Forward To?
Impact of approaches for clinical and radiological monitoring on predicting of short-term and long-term disability outcomes in multiple sclerosis Brian.
Atrophied Brain T2 Lesion Volume at MRI Is Associated with Disability Progression and Conversion to Secondary Progressive Multiple Sclerosis The rate.
Presentation transcript:

What Predicts Disability Progression in Multiple Sclerosis?

Overview: Prognostic Factors in MS

Clinical Prognostic Factors

Early Clinical Events Predict Disability Progression

MRI Prognostic Factors

Gray Matter Atrophy and Loss of Functional Connectivity

Multimodal EPs Predict Risk for Disability

OCT Alterations Predict Development of Disability

Neuronal Damage and Long-Term Synaptic Potentiation

LTP Compensation for Neuronal Damage

Predicting Response to Treatment

BENEFIT Study: Extent of Disease Activity Predicts Treatment Response

BENEFIT Study: Baseline Vitamin D Predicts Time to CDMS

MSCRG Study: Early Predictors of Long-Term Outcomes

MAGNIMS Network: Early Predictors of Short-Term Outcomes

Treating to Target NEDA

NEDA as a Predictor of Brain Atrophy and Optic Nerve Degeneration

CLIMB Cohort Study: Evolution of NEDA Over the Disease Course

NEDA as a Predictor of Long-Term Outcomes

Conclusions

Abbreviations

Abbreviations (cont)